{"generic":"Sorafenib Tosylate","drugs":["NexAVAR","Sorafenib Tosylate"],"mono":{"0":{"id":"jx5rs0","title":"Generic Names","mono":"Sorafenib Tosylate"},"1":{"id":"jx5rs1","title":"Dosing and Indications","sub":[{"id":"jx5rs1b4","title":"Adult Dosing","mono":"<ul><li><b>Liver carcinoma, Unresectable:<\/b> 400 mg ORALLY twice daily at least 1 hour before or 2 hours after eating; continue until patient no longer benefits or until unacceptable toxicity<\/li><li><b>Malignant tumor of thyroid gland, Metastatic or locally advanced, refractory to radioactive iodine:<\/b> 400 mg ORALLY twice daily at least 1 hour before or 2 hours after eating; continue until patient no longer benefits or until unacceptable toxicity<\/li><li><b>Renal cell carcinoma, Advanced:<\/b> 400 mg ORALLY twice daily at least 1 hour before or 2 hours after eating; continue until patient no longer benefits or until unacceptable toxicity<\/li><\/ul>"},{"id":"jx5rs1b5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"jx5rs1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, nondialysis patients:<\/b> no dosage adjustment necessary<\/li><li><b>hepatic impairment, mild or moderate:<\/b> no dosage adjustment necessary; severe impairment has not been studied<\/li><li><b>(hepatocellular or renal cell carcinoma) adverse reactions:<\/b> reduce to 400 mg ORALLY once daily; if additional reduction needed, 400 mg ORALLY once every other day<\/li><li><b>(hepatocellular or renal cell carcinoma) dermatologic toxicity, grade 1, any occurrence:<\/b> continue sorafenib and consider topical therapy for symptomatic relief<\/li><li><b>(hepatocellular or renal cell carcinoma) dermatologic toxicity, grade 2, first occurrence:<\/b> continue sorafenib and consider topical therapy for symptomatic relief; if no improvement within 7 days, interrupt sorafenib until toxicity resolves to grade 0 or 1; then restart and reduce sorafenib dose by 1 level (either to 400 mg ORALLY once daily or 400 mg ORALLY once every other day)<\/li><li><b>(hepatocellular or renal cell carcinoma) dermatologic toxicity, grade 2, second or third occurrence:<\/b> interrupt sorafenib until toxicity resolves to grade 0 or 1; then restart and reduce sorafenib dose by 1 level (either to 400 mg ORALLY once daily or 400 mg ORALLY once every other day)<\/li><li><b> (hepatocellular or renal cell carcinoma) dermatologic toxicity, grade 2, fourth occurrence:<\/b> discontinue sorafenib<\/li><li><b>(hepatocellular or renal cell carcinoma) dermatologic toxicity, grade 3, first or second occurrence:<\/b> interrupt sorafenib until toxicity resolves to grade 0 or 1; then restart and reduce sorafenib dose by 1 level (either to 400 mg ORALLY once daily or 400 mg ORALLY once every other day)<\/li><li><b>(hepatocellular or renal cell carcinoma) dermatologic toxicity, grade 3, third occurrence:<\/b> discontinue sorafenib<\/li><li><b>(thyroid cancer) adverse reactions:<\/b> first reduction to 600 mg\/day (400 mg and 200 mg given 12 hours apart); second reduction to 400 mg\/day in 2 divided doses; third reduction to 200 mg\/day<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 1, any occurrence:<\/b> continue sorafenib<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 2, first occurrence:<\/b> reduce to 600 mg\/day (400 mg and 200 mg given 12 hours apart); if no improvement within 7 days, interrupt sorafenib until toxicity improves to grade 1, and may restart with dose reduced to 200 mg twice daily<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 2, second or third occurrence:<\/b> interrupt sorafenib until toxicity improves to grade 1, and may restart with dose reduced by 1 level (from 400 mg twice daily to 600 mg\/day [given as 400 mg and 200 mg 12 hours apart], or from 600 mg\/day to 400 mg\/day [given as 200 mg twice daily], or from 400 mg\/day to 200 mg once daily)<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 2, fourth occurrence:<\/b> discontinue sorafenib permanently<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 3, first occurrence:<\/b> interrupt sorafenib until toxicity improves to grade 1, and may restart with dose reduced by 1 level (from 400 mg twice daily to 600 mg\/day [given as 400 mg and 200 mg 12 hours apart], or from 600 mg\/day to 400 mg\/day [given as 200 mg twice daily], or from 400 mg\/day to 200 mg once daily)<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 3, second occurrence:<\/b> interrupt sorafenib until toxicity improves to grade 1, and may restart with dose reduced by 2 levels (from 400 mg twice daily to 200 mg twice daily, or from 600 mg\/day to 200 mg once daily)<\/li><li><b>(thyroid cancer) dermatologic toxicity, grade 3, third occurrence:<\/b> discontinue sorafenib permanently<\/li><li><b>(thyroid cancer) dermatologic toxicity:<\/b> following improvement of grade 2 or 3 dermatologic toxicity to grade 0 or 1 after at least 28 days of treatment on a reduced dose, sorafenib may be increased one dose level from the reduced dose<\/li><\/ul>"},{"id":"jx5rs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Liver carcinoma, Unresectable<\/li><li>Malignant tumor of thyroid gland, Metastatic or locally advanced, refractory to radioactive iodine<\/li><li>Renal cell carcinoma, Advanced<\/li><\/ul>"}]},"3":{"id":"jx5rs3","title":"Contraindications\/Warnings","sub":[{"id":"jx5rs3b9","title":"Contraindications","mono":"<ul><li>combination with carboplatin and paclitaxel in patients with squamous cell lung cancer<\/li><li>severe hypersensitivity to sorafenib or any of its components<\/li><\/ul>"},{"id":"jx5rs3b10","title":"Precautions","mono":"<ul><li>cardiac ischemia has been reported; temporary or permanent discontinuation should be considered<\/li><li>concomitant use with gemcitabine and cisplatin in patients with squamous cell lung cancer (unapproved use) is not recommended<\/li><li>concomitant use with strong CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, and St. John's wort), should be avoided<\/li><li>congenital long QT syndrome; avoid use<\/li><li>dermatologic toxicities, some severe and life-threatening (eg, hand-foot skin reaction, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis), have been reported; supportive therapy, temporary interruption, dose modification, or permanent discontinuation may be necessary<\/li><li>gastrointestinal perforation has been reported; some cases were not associated with apparent intraabdominal tumor; discontinuation recommended<\/li><li>hemorrhage, potentially severe and fatal, has occurred; use local therapy for tracheal, bronchial, or esophageal infiltration prior to sorafenib in patients with differentiated thyroid carcinoma; may warrant permanent discontinuation for bleeding requiring medical intervention<\/li><li>hepatitis, including hepatic failure and death, has been reported; monitoring recommended; discontinuation may be necessary<\/li><li>hypertension, potentially severe or persistent, has occurred; monitoring recommended; may require antihypertensive therapy and temporary or permanent discontinuation<\/li><li>myocardial infarction has been reported; temporary or permanent discontinuation should be considered<\/li><li>pregnancy should be avoided; known teratogen<\/li><li>QT\/QTc interval prolongation has been reported; monitoring recommended in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, and in patients receiving other drugs known to prolong the QT interval; temporary interruption may be necessary<\/li><li>surgical procedures, major; may increase the risk of wound healing complications; temporary interruption is recommended<\/li><li>TSH suppression may be impaired in patients with differentiated thyroid carcinoma; monitor and adjust thyroid replacement therapy if necessary<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jx5rs3b11","title":"Pregnancy Category","mono":"<ul><li>Sorafenib: D (FDA)<\/li><li>Sorafenib: D (AUS)<\/li><\/ul>"},{"id":"jx5rs3b12","title":"Breast Feeding","mono":"Sorafenib: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jx5rs4","title":"Drug Interactions","sub":[{"id":"jx5rs4b13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"jx5rs4b14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Droperidol (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Ifosfamide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Neomycin (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Prednisolone (probable)<\/li><li>Primidone (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Salmeterol (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"},{"id":"jx5rs4b15","title":"Moderate","mono":"<ul><li>Docetaxel (probable)<\/li><li>Doxorubicin (probable)<\/li><li>Doxorubicin Hydrochloride Liposome (probable)<\/li><li>Thiotepa (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"jx5rs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, All grades (19.1%)<\/li><li><b>Dermatologic:<\/b>Acral erythema (hepatocellular carcinoma, 21%; renal cell carcinoma, 30%; thyroid carcinoma, 69%), Alopecia (hepatocellular carcinoma, 14%; renal cell carcinoma, 27%; thyroid carcinoma, 67%), Peeling of skin, Rash (up to 35%)<\/li><li><b>Endocrine metabolic:<\/b>Hypoalbuminemia (hepatocellular carcinoma, 59%), Hypocalcemia (hepatocellular carcinoma, 27%; renal cell carcinoma, 12%; thyroid carcinoma, 36%), Hypophosphatemia (35% to 45%), Raised TSH level (thyroid carcinoma, 41%), Weight decreased (hepatocellular carcinoma, 30%; renal cell carcinoma, 10%; thyroid carcinoma, 49%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (renal cell carcinoma, 11%; hepatocellular carcinoma, 31%; thyroid carcinoma, 20%), Decrease in appetite (thyroid carcinoma, 30%), Diarrhea (43% to 68%), Increased serum lipase level (40% to 41%), Loss of appetite (16% to 29%), Nausea (21% to 24%), Serum amylase raised (30% to 34%)<\/li><li><b>Hematologic:<\/b>Lymphocytopenia (renal cell carcinoma, 23%; hepatocellular carcinoma, 47%), Thrombocytopenia (renal cell carcinoma; 12%; hepatocellular carcinoma, 46%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, All grades (thyroid carcinoma, 59%), AST\/SGOT level raised, All grades (thyroid carcinoma, 54%)<\/li><li><b>Immunologic:<\/b>Infectious disease (10% or greater)<\/li><li><b>Other:<\/b>Fatigue (37% to 46%), Pain (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure (1.9%), Hypertension, Grade 3 or 4 (4.3%), Hypertensive crisis (0.1% to less than 1%), Myocardial infarction, Myocardial ischemia, Prolonged QT interval (Less than 0.1%)<\/li><li><b>Dermatologic:<\/b>Squamous cell carcinoma of skin (thyroid carcinoma, 3%), Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage, Gastrointestinal perforation (0.1% to less than 1%), Pancreatitis (0.1% to less than 1%)<\/li><li><b>Hematologic:<\/b>Hemorrhage (renal cell carcinoma, 15.3%; thyroid carcinoma, 17.4%)<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised, Grade 3 or higher (thyroid carcinoma, 4%), AST\/SGOT level raised, Grade 3 or 4 (thyroid carcinoma, 2%), Hepatitis (less than 0.1%)<\/li><li><b>Neurologic:<\/b>Cerebral hemorrhage (0.1% to less than 1%), Posterior reversible encephalopathy syndrome (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Interstitial lung disease (0.1% to less than 1%), Respiratory tract hemorrhage<\/li><\/ul>"},"6":{"id":"jx5rs6","title":"Drug Name Info","sub":{"0":{"id":"jx5rs6b17","title":"US Trade Names","mono":"NexAVAR<br\/>"},"2":{"id":"jx5rs6b19","title":"Class","mono":"Antineoplastic Agent<br\/>"},"3":{"id":"jx5rs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jx5rs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jx5rs7","title":"Mechanism Of Action","mono":"Sorafenib is an inhibitor of multiple intracellular and cell surface kinases, inhibiting tumor growth and angiogenesis of human hepatocellular carcinoma and renal cell carcinoma.<br\/>"},"8":{"id":"jx5rs8","title":"Pharmacokinetics","sub":[{"id":"jx5rs8b23","title":"Absorption","mono":"<ul><li>Bioavailability, oral tablet: 38% to 49% compared with oral solution<\/li><li>Effect of food: decreased bioavailability by 29% with high-fat meal (50% fat)<\/li><li>Tmax, oral: 3 hours<\/li><\/ul>"},{"id":"jx5rs8b24","title":"Distribution","mono":"Protein binding: 99.5% <br\/>"},{"id":"jx5rs8b25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>Pyridine n-oxide: active metabolite<\/li><li>substrate of CYP3A4 and UGT1A9<\/li><li>inhibitor of P-glycoprotein, UGT1A1, and UGT1A9 in vitro<\/li><\/ul>"},{"id":"jx5rs8b26","title":"Excretion","mono":"<ul><li>Fecal: 51% unchanged<\/li><li>Renal: 19% glucuronidated metabolites<\/li><\/ul>"},{"id":"jx5rs8b27","title":"Elimination Half Life","mono":"25 to 48 hours <br\/>"}]},"9":{"id":"jx5rs9","title":"Administration","mono":"<b>Oral<\/b><br\/>take at least 1 hour before or 2 hours after a meal <br\/>"},"10":{"id":"jx5rs10","title":"Monitoring","mono":"<ul><li>clinical or radiologic evidence of tumor regression is indicative of efficacy<\/li><li>unresectable hepatocellular carcinoma: serum alpha-fetoprotein levels; surrogate marker of disease stabilization and prognosis<\/li><li>electrolytes (magnesium, potassium, calcium), in patients with congestive heart failure, bradyarrhythmias, or concomitant drug therapy known to prolong the QT interval (eg, Class Ia and III antiarrhythmics)<\/li><li>liver function tests; regularly<\/li><li>TSH levels; monthly in patients with differentiated thyroid carcinoma<\/li><li>blood pressure; weekly during the first 6 weeks of therapy and periodically thereafter<\/li><li>ECG for QT interval prolongation, in patients with congestive heart failure, bradyarrhythmias, or concomitant drug therapy known to prolong the QT interval including Class Ia and III antiarrhythmics<\/li><\/ul>"},"11":{"id":"jx5rs11","title":"How Supplied","mono":"<b>NexAVAR<\/b><br\/>Oral Tablet: 200 MG<br\/>"},"12":{"id":"jx5rs12","title":"Toxicology","sub":[{"id":"jx5rs12b31","title":"Clinical Effects","mono":"<b>SORAFENIB<\/b><br\/>OVERDOSE: Sorafenib overdose information is limited. Doses of 800 mg twice daily, given during clinical trials, have resulted in diarrhea and grade 3 hypertension, dyspnea and rash\/desquamation. ADVERSE EFFECTS: Common adverse effects with sorafenib therapy include fatigue, hypertension, rash\/desquamation, hand-foot skin reaction, hypophosphatemia, alopecia, gastrointestinal effects (nausea, vomiting and diarrhea), bleeding at all sites and sensory neuropathy. Other adverse effects that may occur with sorafenib therapy include weight loss, dry skin, constipation, neutropenia, thrombocytopenia, joint pain and headache.<br\/>"},{"id":"jx5rs12b32","title":"Treatment","mono":"<b>SORAFENIB<\/b><br\/><ul><li>Decontamination: Activated charcoal.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Hypertensive disorder: Monitor vital signs regularly.  For mild\/moderate asymptomatic hypertension, pharmacologic treatment is generally not necessary.  Sedation with benzodiazepines in agitated patients with hypertension and tachycardia.  For severe hypertension, nitroprusside is preferred. Labetalol, nitroglycerin and phentolamine are alternatives.<\/li><li>Eruption: Use topical emollient of 2% ketoconazole or topical steroids in patients with facial erythematous rash. Onset is usually 1 to 2 weeks after the start of therapy and it typically fades or disappears with continued therapy.<\/li><li>Monitoring of patient: Monitor CBC with differential and platelet count periodically following overdose. Monitor fluid and electrolyte levels in patients with significant vomiting and\/or diarrhea.<\/li><li>Enhanced elimination procedure: There is no information regarding the effectiveness of hemodialysis or hemoperfusion for the removal of sorafenib from plasma; however, due to its high protein binding (99.5%), it is anticipated that hemodialysis would NOT be effective.<\/li><\/ul>"},{"id":"jx5rs12b33","title":"Range of Toxicity","mono":"<b>SORAFENIB<\/b><br\/>TOXICITY: Doses of 800 mg given twice daily have resulted in diarrhea and grade 3 hypertension, dyspnea and rash\/desquamation. ADULT THERAPEUTIC DOSE: 400 mg orally twice daily. <br\/>"}]},"13":{"id":"jx5rs13","title":"Clinical Teaching","mono":"<ul><li>Adverse effects to a fetus may be caused by either male or female patients receiving treatment with this drug. Emphasize the use of reliable contraception during treatment and for at least 2 weeks after therapy.<\/li><li>Drug may cause fatigue, weight loss, anorexia, alopecia, dry skin, and gastrointestinal reactions (abdominal pain, constipation, diarrhea, nausea, vomiting).<\/li><li>Instruct patient to report bleeding or signs\/symptoms of gastrointestinal perforation (nausea, vomiting, severe abdominal pain).<\/li><li>Advise patient to immediately report chest pain or other signs\/symptoms of cardiac ischemia or infarction.<\/li><li>Advise patient to report signs\/symptoms of QT prolongation (syncope, dizziness, edema), a hand-foot skin reaction (palmer-plantar erythema, numbness, and tingling) or skin rash, including Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, skin\/mucosus membrane blistering), or symptoms of hepatitis.<\/li><li>Instruct patient to monitor blood pressure regularly during treatment (especially during the first 6 weeks).<\/li><li>Patient should take drug 1 hour before or 2 hours after ingestion of food.<\/li><\/ul>"}}}